Funding Announcements

"First Concepts has a simple mission to transform creative context from something fragile and ephemeral into a structured, compounding asset. We are building an operating system that understands the value of creative thinking and taste. This will transform creative workflows for teams around the world."

"Chorus is a fast-growing business which is operating in a market experiencing strong structural growth. Digital intelligence is becoming an essential component of modern investigations. Chorus has invested heavily in technology, with its next-generation CIS platform already delivering measurable efficiency gains and return on investment for customers in both the UK and US. We are delighted to support the team as they continue to scale the business, expand its international presence and further enhance the platform’s capabilities to support its customers."

"This funding is a powerful endorsement of our team’s ability to bring breakthrough products to the hands of growers, exporters and consumers around the world. We are entering a new era, one where gene‑edited crops will significantly enhance food security and sustainability. 2025 proved that our technology delivers – not in the distant future, but right now. With two banana varieties already on the market and demand outstripping supply, this investment enables us to scale global production and expand into new crops faster than ever before. We are excited to be partnering with our new investors as we progress our mission to build a world-leading tropical seeds company."

"Our focus from day one has been on building a new type of silicon battery material that can be produced at scale and integrated into existing battery supply chains. This investment allows us to move beyond proof-of-concept and concentrate on scaling a product that delivers real commercial value to battery manufacturers, without introducing unnecessary cost or complexity."

"Combat Medicalis leading the development and clinical use of device assisted therapies with potential to disrupt current treatment standards. With systems in wide clinical use and already impacting patient outcomes, we are excited to support the company as HIVEC progresses through clinical trials."